CORDIS
EU research results

CORDIS

English EN

News

English EN

Widely used blood pressure drugs might put heart at risk

Using real-world data from two European countries, scientists have found that a certain type of drug prescribed to lower blood pressure may actually increase the risk of cardiac arrest.

HEALTH

Scientific advances

© lovelyday12, Shutterstock

Drugs based on a molecule called dihydropyridine are commonly prescribed by doctors to treat high blood pressure and angina, a chest pain caused by reduced blood flow to the heart. However, there’s a chance that these same drugs increase the risk of sudden cardiac arrest (SCA). Because the heart stops pumping blood to the heart and other vital organs during an SCA, failure to receive timely treatment can be lethal. SCA is responsible for up to half of all deaths caused by cardiovascular diseases in industrialised countries. Most of the time, it’s the result of lethal heartbeat irregularities following disruptions in the heart’s electrical activity. Such disruptions can be caused by a number of factors affecting the heart’s ion channels. When these channels are blocked, the action potential of cardiac cells becomes shorter. Action potential refers to the change in electrical potential when an impulse travels along the membrane of a muscle cell or nerve cell. When the action potential duration is shortened, this may cause the aforementioned heartbeat irregularities referred to as ventricular tachycardia/fibrillation (VT/VF). Because they block cardiac calcium channels, there have been concerns that dihydropyridine-based drugs increase the risk of SCA. Researchers supported by the EU-funded project ESCAPE-NET set out to establish whether this is true. In their study, they sought to determine whether nifedipine and amlodipine, the two most commonly prescribed dihydropyridines in the Netherlands, are linked to a higher risk of out-of-hospital cardiac arrest (OHCA). The scientists conducted case-control studies using data from population-based emergency medical services-attended OHCA registries in Denmark and the Netherlands. The cases studied were OHCA victims over 18 years of age with documented VT/VF from presumed cardiac causes. A total of 2 503 OHCA cases were matched to 10 543 non-OHCA controls in the Dutch registry, and 8 101 OHCA cases were matched to 40 505 non-OHCA controls in the Danish registry.

Research results on the two calcium channel blockers

According to the study’s findings, high-dose nifedipine is associated with a higher risk of OHCA in the general population. However, this doesn’t apply to low-dose nifedipine or any dose of amlodipine. The researchers found differences in the cellular electrophysiological properties of clinically used concentrations between both drugs, and recommend careful titration of nifedipine. As the authors explain in the study, “AP-shortening may contribute to the increase in OHCA risk of high-dose nifedipine. This may also explain why high-dose nifedipine, but not low-dose nifedipine or amlodipine, is associated with increased OHCA risk: high-dose nifedipine causes more AP-shortening than both other conditions. Of note, although amlodipine blocks cardiac L-type calcium-channels at similar concentrations as nifedipine, the extent of ICa,L block in clinical practice is lower for amlodipine than for nifedipine, because prescribed dosages (and plasma-concentrations) are significantly lower for amlodipine.” The findings of the ESCAPE-NET (European Sudden Cardiac Arrest network: towards Prevention, Education and NEw Treatment) project provide clues that may help form future strategies to prevent this adverse nifedipine effect. According to the authors, such strategies might have to involve identifying vulnerable individuals and limiting prescribed dosages. For more information, please see: ESCAPE-NET project website

Countries

Netherlands